Regenicin Inc.
Regenicin, Inc. focuses on developing and commercializing the technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company's products are used to restore the qualities of hea… Read more
Regenicin Inc. (RGIN) - Net Assets
Latest net assets as of March 2023: $-6.21 Million USD
Based on the latest financial reports, Regenicin Inc. (RGIN) has net assets worth $-6.21 Million USD as of March 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.86 Million) and total liabilities ($18.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-6.21 Million |
| % of Total Assets | -52.37% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 50.67 |
Regenicin Inc. - Net Assets Trend (2010–2022)
This chart illustrates how Regenicin Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Regenicin Inc. (2010–2022)
The table below shows the annual net assets of Regenicin Inc. from 2010 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-09-30 | $-5.60 Million | -8.38% |
| 2021-09-30 | $-5.16 Million | -20.46% |
| 2020-09-30 | $-4.29 Million | -15.01% |
| 2019-09-30 | $-3.73 Million | -24.25% |
| 2018-09-30 | $-3.00 Million | -22.88% |
| 2017-09-30 | $-2.44 Million | -66.31% |
| 2016-09-30 | $-1.47 Million | -91.14% |
| 2015-09-30 | $-768.04K | +49.36% |
| 2014-09-30 | $-1.52 Million | +63.36% |
| 2013-09-30 | $-4.14 Million | -810.87% |
| 2012-09-30 | $-454.48K | -128.09% |
| 2011-09-30 | $1.62 Million | -26.75% |
| 2010-09-30 | $2.21 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Regenicin Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1595585000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $157.91K | % |
| Other Components | $10.20 Million | % |
| Total Equity | $-5.60 Million | 100.00% |
Regenicin Inc. Competitors by Market Cap
The table below lists competitors of Regenicin Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SINO LAND CO
BE:SNO
|
$12.56K |
|
The Marketing Alliance Inc
PINK:MAAL
|
$12.57K |
|
Danang Airport Services JSC
VN:MAS
|
$12.58K |
|
Gemfields Plc
LSE:GEM
|
$12.59K |
|
Flexpoint Sensor Systems Inc
PINK:FLXT
|
$12.55K |
|
Vietnam Maritime Development JSC
VN:VMS
|
$12.55K |
|
Abak SA
WAR:ABK
|
$12.54K |
|
Kornic Automation Co. Ltd.
KO:391710
|
$12.52K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Regenicin Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -5,164,378 to -5,597,140, a change of -432,762.
- Net loss of 694,041 reduced equity.
- Other factors increased equity by 261,279.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-694.04K | -12.4% |
| Other Changes | $261.28K | +4.67% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Regenicin Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-09-30 | $0.00 | $0.00 | x |
| 2008-09-30 | $0.00 | $0.00 | x |
| 2009-09-30 | $0.00 | $0.00 | x |
| 2010-09-30 | $0.03 | $0.00 | x |
| 2011-09-30 | $0.02 | $0.00 | x |
| 2012-09-30 | $-0.01 | $0.00 | x |
| 2013-09-30 | $-0.04 | $0.00 | x |
| 2014-09-30 | $-0.01 | $0.00 | x |
| 2015-09-30 | $0.00 | $0.00 | x |
| 2016-09-30 | $-0.01 | $0.00 | x |
| 2017-09-30 | $-0.02 | $0.00 | x |
| 2018-09-30 | $-0.02 | $0.00 | x |
| 2019-09-30 | $-0.02 | $0.00 | x |
| 2020-09-30 | $-0.03 | $0.00 | x |
| 2021-09-30 | $-0.03 | $0.00 | x |
| 2022-09-30 | $-0.04 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Regenicin Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-17.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -10.26% | 0.00% | 0.00x | 1.00x | $-7.90K |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-43.95K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.35K |
| 2010 | -42.35% | 0.00% | 0.00x | 1.38x | $-1.16 Million |
| 2011 | -226.59% | 0.00% | 0.00x | 1.91x | $-3.83 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.10 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.49 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $153.74K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $319.40K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-943.20K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-729.79K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-259.05K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-403.64K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-177.91K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-395.38K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-134.33K |
Industry Comparison
This section compares Regenicin Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Regenicin Inc. (RGIN) | $-6.21 Million | -10.26% | N/A | $12.56K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |